Name: VERTEX PHARMACEUTICALS INC (VRTX) Stock
Brand: VERTEX PHARMACEUTICALS INC
Rating: 6.5 (3 reviews)

VRTX Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Chartmill

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Presents a Compelling Case for Value Investors

17 days ago - By: Chartmill

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Top Affordable Growth Stock

a day ago - By: The Motley Fool

Vertex (VRTX) Q3 2025 Earnings Call Transcript

2 days ago - By: The Motley Fool - Mentions: MRNA

Where Will Vertex Pharmaceuticals Be in 5 Years

9 days ago - By: Vertex Pharmaceuticals Incorporated

Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3

9 days ago - By: Benzinga

Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today

10 days ago - By: Zacks Investment Research

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

11 days ago - By: Benzinga

Is Vertex Pharmaceuticals Inc Gaining or Losing Market Support?

17 days ago - By: Zacks Investment Research - Mentions: ALKS CRMD CRSP

CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates

20 days ago - By: Vertex Pharmaceuticals Incorporated

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

21 days ago - By: Zacks Investment Research

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

23 days ago - By: Zacks Investment Research - Mentions: ANIP NTLA CRSP

VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?

24 days ago - By: Zacks Investment Research - Mentions: ANIP NTLA CRSP

Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint

25 days ago - By: Zacks Investment Research

Vertex (VRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

25 days ago - By: Zacks Investment Research - Mentions: CGEN

Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates

25 days ago - By: Investor's Business Daily

Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book

25 days ago - By: Bloomberg

Vertex Beats Estimates on Strong Sales of Cystic Fibrosis Drugs

25 days ago - By: Vertex Pharmaceuticals Incorporated

Vertex Reports Third Quarter 2025 Financial Results

25 days ago - By: Zacks Investment Research - Mentions: BEAM NTLA CRSP

VERTEX PHARMACEUTICALS INC (VRTX) Stock News

VRTX Latest News, Press Relases and Analysis

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Presents a Compelling Case for Value Investors

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Top Affordable Growth Stock

Vertex (VRTX) Q3 2025 Earnings Call Transcript

Where Will Vertex Pharmaceuticals Be in 5 Years

Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3

Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Is Vertex Pharmaceuticals Inc Gaining or Losing Market Support?

CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?

Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint

Vertex (VRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates

Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book

Vertex Beats Estimates on Strong Sales of Cystic Fibrosis Drugs

Vertex Reports Third Quarter 2025 Financial Results

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?